DiagnosTear got an approval for a second year grant from the Office of the Chief Scientist

BioLight announces that its subsidiary DiagnosTear Ltd., in which the Company holds 70% of the issued and outstanding share capital, notified the Company that a second year approval for a grant from the Office of the Chief Scientist for a project with respect to the development of a diagnostic test intended for the diagnosis and monitoring of treatment of dry eye syndrome was received and approved.

Link to the complete article

Link to Newsroom

Comments are closed